


Top 31-35

09 June 2011 | News



DiagnoSearch Life Sciences

Founder and MD
Dr Vasudeo Ginde

31

Business: Offering a complete range of clinical trials support services

Start-up Year: 1975

Address: 101, First Floor, B G House, Orchard Avenue, Hiranandani, Business Park, Mumbai-400076

Tel: +91-22-66976300

Fax: +91-22-66754090

Website: www.diagnosearch.com

DiagnoSearch Life Sciences, formerly iGate Clinical Research, recorded revenues of IN 121 crore for 2010-11 as against previous year's revenue of IN 97 crore. DiagnoSearch has passed over 100 CQA audits by North American and European biopharmaceutical companies and offers a complete range of phase I to IV clinical trials support services. Over the past 12 years, DiagnoSearch managed over 100 clinical trials for global sponsors in a broad range of therapeutic areas. The company has a headcount of more than 100 staff and is going to come up with a new 30,000 sq ft office facility. The firm mainly operates using three divisions, namely, clinical operations, monitoring and the project management division. The firm has a central laboratory that offers comprehensive solutions including, production of bar-coded, visit-specific kits, investigator team training, state-of-the-art analytical methods, efficient specimen shipment and automated data reporting.

Revenue:  121 crore



Veeda Clinical Research

Founders & MDs
Mr Apurva Shah &
Mr Binoy Gardi

Business: Specializes in early clinical development

Start-up Year: 2005




32


Address: Veeda Clinical Research – India, Shivalik Plaza-A, Near IIM, Ambawadi, Ahmedabad- 380015

Tel: +91-79-30013000 **Fax:** +91-79-30013010

Website: www.veedacr.com

Revenue:  120 crore

Veeda Clinical Research, is a full service global CRO specializing in early clinical development of drugs (phase I and IIa) with state-of-the-art facilities in the UK, India and Belgium. It recorded revenues of  120 crore during the FY 2010-11 as against last year's revenue of  112 crore, with a growth of about 7.14 percent. Veeda has been growing at a rate of 70 percent since its inception and aims to achieve a turnover of  325 crore in the next three years. The firm has acquired four CROs in Europe and presently houses state-of-the-art phase I facilities in Plymouth, UK; Ahmedabad, India and Görlitz, Germany. In October 2010, Veeda announced the opening of its facility at Ahmedabad, spread across three floors with an area of 25,000 sq ft. In May 2011, Veeda announced that the final steps have been put in place for the commissioning of its CRC Veeda (Malaysia) phase I unit in the Ampang Hospital in Kuala Lumpur, Malaysia.



Intas Biopharmaceutical

CEO (MD)
Dr Urmish Chudgar

Business: R&D, manufacturing & marketing of recombinant products and oncology drugs

Start-up Year: 2006

33





Address: Plot No 423/P/A/GIDC, Moraiya, Sarkhej-Bavla highway, Tal: Sanand, Ahmedabad-382210


Tel: +91-2717-660101

Fax: +91-2717-251189

Website: www.intasbiopharma.co.in

Revenue:  110 crore

Intas Biopharmaceutical (IBPL) clocked revenue of  110 crore in FY 2010-11 as compared to  115 crore in the previous FY. Intas Pharmaceuticals, IBPL's parent company has filed its red herring prospectus (DRHP) with SEBI and is looking to raise  425 crore. The firm has presently developed and commercialized five products in India and other semi-regulated markets in Africa, Latin America and Asia Pacific and has an additional 11 projects at advanced stages of development, out of which, nine projects are for the Indian market and two are for regulated markets. IBPL also intends to invest  15.33 crore at the Moraiya facility.

The company launched bortezomib injection, under the brand name Borviz, which is expected to offer an effective treatment for multiple myeloma. The company will also invest  160 crore towards setting up a manufacturing facility at Sanand, near Ahmedabad, to produce monoclonal antibodies with a capacity of 5,000 liter in phases.





Diagnova (A division of RFCL)

MD
Mr Sushil Mehta


Business: Diagnostics

34

Diagnova is the diagnostic division of RFCL, which is now part of US-based Avantor Performance Materials. In FY 2010-11, Diagnova recorded a sluggish growth with revenues of  103 crore as compared to  100 crore in the FY 2009-10. This firm's manufacturing plant is situated in Dehradun, Uttarakhand, and the company offers quality products and services to over 6,000 customers. The business of Diagnova is divided into three strategic units: In Vitro Diagnostics (IVD), Medical Sciences Group (MSG) and Life Sciences Group (LSG). Diagnova has an ISO certified manufacturing setup for IVD products based at Haridwar, Uttaranchal. The MSG Group of Diagnova markets medical devices in the field of gastroenterology with a product profile that covers pH & motility systems, breath test analyzer, cardiac

Start-up Year:

2005

Address: A-3, Okhla Industrial Area Phase-I, New Delhi-110 020**Tel:** +91-11-42395700**Fax:** +91-11-41609189**Website:** www.rfcl.in/dignova, www.diagnova.in**Revenue:** ₹103 crore**Vimta Labs**

CMD

Dr S P Vasireddi

35**Business:** Contract research**Start-up Year:** 1984**Address:** 142, IDA, Phase II, Cherlapally, Hyderabad-500 051**Tel:** +91-40-27264141**Fax:** +91-40-27263657**Website:** www.vimta.com**Revenue:** ₹96.5 crore

Vimta Labs, one of India's leading contract research and testing organization, reported a revenue of ₹96.5 crore in FY 2010-11 as compared to ₹88.42 crore in 2009-10.

The company employs 756 personnel, including 479 scientists, and boasts of more than 300,000 sq ft of world class laboratory facilities. Vimta Labs achieved AAALAC International full accreditation in February, 2011, and the company conducts its operations in compliance with ICH-GCP and GLP. The company has a large bioanalytical group, equipped with 26 mass spectrometers across two sites, operational round the clock. Over 200 bioanalytical methods have been developed and validated at Vimta Labs and the firm conducted over 1,100 BA/BE studies on various dosage forms such as tablets, capsules, extended release preparations, gels, jelly's, solutions, transdermal patches and injectibles among others.